



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

## Contents

Introduction .....	3
Patient-centred care.....	6
Strength of recommendations .....	7
Key priorities for implementation.....	9
1 Recommendations .....	12
Terms used in this guideline.....	12
1.1 Principles and protocols for intravenous fluid therapy.....	12
1.2 Assessment and monitoring.....	13
1.3 Fluid resuscitation .....	16
1.4 Routine maintenance .....	16
1.5 Replacement and redistribution .....	18
1.6 Managing hypernatraemia that develops during intravenous fluid therapy .....	18
1.7 Managing hyponatraemia that develops during intravenous fluid therapy .....	19
1.8 Training and education .....	21
2 Research recommendations .....	29
3 Other information .....	31
4 The Guideline Development Group, National Collaborating Centre and NICE project team, and declarations of interests .....	33

## 1 Introduction

This guideline contains recommendations about general principles for managing intravenous (IV) fluids in children and young people under 16 years, and applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions.

2

3 Correct fluid and electrolyte balance is essential to maintain physiological  
4 function. Normally, children and young people get the fluid they need by  
5 drinking. Many children and young people admitted to hospital may be too ill  
6 to drink so may need intravenous (IV) fluid therapy to correct or maintain their  
7 fluid and electrolyte balance.

8 Children and young people may need IV fluids to account for losses of red  
9 blood cells, plasma, water or electrolytes beyond the usual losses in urine,  
10 stools and sweat. These losses can come from burns, diarrhoea, vomiting or  
11 leakage of fluid into the interstitial space. In these cases the aim is to replace  
12 any depleted fluids and restore electrolyte balance. Conditions such as  
13 cardiac dysfunction, liver disease, inappropriate antidiuretic hormone  
14 secretion and nephrotic syndrome can result in an excess of fluids in the  
15 body, known as fluid overload. If this happens, the aim is to rebalance and  
16 redistribute fluids and ensure the correct levels of electrolytes.

17 Whether IV fluid therapy is needed for fluid resuscitation, routine  
18 maintenance, replacement or redistribution, it is vital that the correct  
19 composition, volume and timing of IV fluid therapy is used. IV fluid types  
20 include colloids, crystalloids and combinations of fluids, and different types of  
21 fluids are appropriate for different situations. Errors in prescribing or  
22 administering IV fluids can result in inadequate or excessive provision, leading  
23 to hypovolaemia and poor organ perfusion, or hypervolaemia, oedema and  
24 heart failure. Failing to correct imbalances in electrolytes can lead to  
25 disturbances in intracellular or extracellular electrolyte balance, particularly in  
26 children and young people with reduced liver or kidney function. Failing to

1 deliver correct fluids can therefore have a significant impact on morbidity and  
2 mortality.

3 Surveys have shown that many staff who prescribe IV fluids know neither the  
4 likely fluid and electrolyte needs of individual patients, nor the specific  
5 composition of the many choices of IV fluids available to them. There is little  
6 formal training and education in IV fluid management to support correct  
7 prescribing.

8 There is also a wide variation in the charts used to prescribe fluids and to  
9 record fluid and electrolyte status. Monitoring children and young people is  
10 often challenging: it may be difficult to assess urine output accurately, and  
11 blood tests can be painful, distressing and difficult to repeat. Assessment and  
12 monitoring is often suboptimal, and fluid and electrolyte status may not be  
13 recorded accurately. Changes in patients' fluid needs may not be reassessed  
14 appropriately or at the correct intervals, which can lead to fluids being  
15 prescribed incorrectly. Clinical staff need to ensure that appropriate  
16 identification, treatment and monitoring of changes in fluid and electrolyte  
17 status is maintained and documented. There is a need for a standardised  
18 approach to assessing patients' fluid and electrolyte status and prescribing IV  
19 fluid therapy in the NHS. This guidance represents a major opportunity to  
20 improve patient safety for children and young people having IV fluid therapy in  
21 hospital.

## 22 ***Safeguarding children***

23 Remember that child maltreatment:

- 24 • is common
- 25 • can present anywhere, such as emergency departments and primary care  
26 or on home visits.

27 Be aware of or suspect abuse as a contributory factor to or cause of the  
28 symptoms or signs of dehydration in children. Abuse may also coexist with  
29 dehydration. See the NICE guideline on [child maltreatment](#) for clinical features  
30 that may be associated with maltreatment.

1 **Medicines**

2 The guideline will assume that prescribers will use a medicine's summary of  
3 product characteristics to inform decisions made with individual patients.

4 This guideline recommends some medicines for indications for which they do  
5 not have a UK marketing authorisation at the date of publication, if there is  
6 good evidence to support that use. The prescriber should follow relevant  
7 professional guidance, taking full responsibility for the decision. The patient  
8 (or those with authority to give consent on their behalf) should provide  
9 informed consent, which should be documented. See the General Medical  
10 Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further  
11 information. Where recommendations have been made for the use of  
12 medicines outside their licensed indications ('off-label use'), these medicines  
13 are marked with a footnote in the recommendations.

14

## 1 **Patient-centred care**

2 This guideline offers best practice advice on the care of children and young  
3 people who need intravenous (IV) fluids.

4 Patients and healthcare professionals have rights and responsibilities as set  
5 out in the [NHS Constitution for England](#) – all NICE guidance is written to  
6 reflect these. Treatment and care should take into account individual needs  
7 and preferences. Patients should have the opportunity to make informed  
8 decisions about their care and treatment, in partnership with their healthcare  
9 professionals. If the patient is under 16, their family or carers should also be  
10 given information and support to help the child or young person to make  
11 decisions about their treatment. If it is clear that the child or young person fully  
12 understands the treatment and does not want their family or carers to be  
13 involved, they can give their own consent. Healthcare professionals should  
14 follow the [Department of Health's advice on consent](#). If someone does not  
15 have capacity to make decisions, healthcare professionals should follow the  
16 [code of practice that accompanies the Mental Capacity Act](#) and the  
17 supplementary [code of practice on deprivation of liberty safeguards](#).

18 If a young person is moving between paediatric and adult services, care  
19 should be planned and managed according to the best practice guidance  
20 described in the Department of Health's [Transition: getting it right for young](#)  
21 [people](#).

22 Adult and paediatric healthcare teams should work jointly to provide  
23 assessment and services to young people who need IV fluids. Diagnosis and  
24 management should be reviewed throughout the transition process, and there  
25 should be clarity about who is the lead clinician to ensure continuity of care.

26

## 1 **Strength of recommendations**

2 Some recommendations can be made with more certainty than others. The  
3 Guideline Development Group makes a recommendation based on the trade-  
4 off between the benefits and harms of an intervention, taking into account the  
5 quality of the underpinning evidence. For some interventions, the Guideline  
6 Development Group is confident that, given the information it has looked at,  
7 most patients would choose the intervention. The wording used in the  
8 recommendations in this guideline denotes the certainty with which the  
9 recommendation is made (the strength of the recommendation).

10 For all recommendations, NICE expects that there is discussion with the  
11 patient about the risks and benefits of the interventions, and their values and  
12 preferences. This discussion aims to help them to reach a fully informed  
13 decision (see also 'Patient-centred care').

### 14 ***Interventions that must (or must not) be used***

15 We usually use 'must' or 'must not' only if there is a legal duty to apply the  
16 recommendation. Occasionally we use 'must' (or 'must not') if the  
17 consequences of not following the recommendation could be extremely  
18 serious or potentially life threatening.

### 19 ***Interventions that should (or should not) be used – a 'strong'*** 20 ***recommendation***

21 We use 'offer' (and similar words such as 'refer' or 'advise') when we are  
22 confident that, for the vast majority of patients, an intervention will do more  
23 good than harm, and be cost effective. We use similar forms of words (for  
24 example, 'Do not offer...') when we are confident that an intervention will not  
25 be of benefit for most patients.

### 26 ***Interventions that could be used***

27 We use 'consider' when we are confident that an intervention will do more  
28 good than harm for most patients, and be cost effective, but other options may  
29 be similarly cost effective. The choice of intervention, and whether or not to

## DRAFT FOR CONSULTATION

- 1 have the intervention at all, is more likely to depend on the patient's values
- 2 and preferences than for a strong recommendation, and so the healthcare
- 3 professional should spend more time considering and discussing the options
- 4 with the patient.

5



1

## 2 **Key priorities for implementation**

3 The following recommendations have been identified as priorities for  
4 implementation. The full list of recommendations is in section 1 [\[hyperlink to](#)  
5 [be added for final publication\]](#).

### 6 **Assessment and monitoring**

- 7 • In neonates, children and young people who are receiving IV fluids, assess  
8 and document the following on the fluid balance and prescription chart:
  - 9 – Actual or estimated body weight from the previous day, the current day  
10 and the difference between the 2, or body surface area if used (see  
11 recommendation 1.2.2).
  - 12 – Fluid input, output and balance over the previous 24 hours.
  - 13 – Any special instructions for prescribing, including relevant history.
  - 14 – An assessment of the fluid status.
  - 15 – The results of laboratory and point-of-care assessments, including:
    - 16 ◇ full blood count
    - 17 ◇ urea
    - 18 ◇ creatinine
    - 19 ◇ plasma electrolyte concentrations (including chloride, sodium and  
20 potassium; see recommendation 1.2.4)
    - 21 ◇ blood glucose (see recommendation 1.2.5)
    - 22 ◇ urinary electrolyte concentrations.
  - 23 – Details of any ongoing losses (see recommendation 1.5.1 and the  
24 [diagram of ongoing losses](#)).
  - 25 – Calculations of fluid needs for routine maintenance, replacement,  
26 redistribution and resuscitation.
  - 27 – The fluid and electrolyte prescription (in ml per hour), with clear  
28 signatures, dates and times.
  - 29 – Fluid limits.
  - 30 – Types and volumes of fluid input and output (urine, gastric and other),  
31 recorded hourly and with running totals.

- 1 – 12-hourly fluid balance subtotals.
- 2 – 24-hourly fluid balance totals.
- 3 – 12-hourly reassessments of:
  - 4 ◇ the fluid prescription
  - 5 ◇ current hydration status
  - 6 ◇ whether oral fluids can be started
  - 7 ◇ potassium requirements
  - 8 ◇ urine and other outputs. **[1.2.3]**

### 9 **Fluid resuscitation**

- 10 • If children and young people need IV fluid resuscitation, use glucose-free  
11 crystalloids<sup>1</sup> that contain sodium in the range 130–154 mmol/litre, with a  
12 bolus of 20 ml/kg over less than 10 minutes. **[1.3.1]**
- 13 • If neonates need IV fluid resuscitation, use glucose-free crystalloids<sup>1</sup> that  
14 contain sodium in the range 130-154 mmol/litre, with a bolus of 10-20 ml/kg  
15 over less than 10 minutes. **[1.3.2]**

### 16 **Routine maintenance**

- 17 • If children and young people need IV fluids for routine maintenance, initially  
18 use isotonic crystalloids<sup>2</sup> that contain sodium in the range 130–  
19 154 mmol/litre. **[1.4.3]**
- 20 • Measure plasma electrolyte concentrations and blood glucose when  
21 starting IV fluids for routine maintenance (except before most elective  
22 surgery), and at least every 24 hours thereafter. **[1.4.4]**
- 23 • If neonates need IV fluids for routine maintenance, initially use isotonic  
24 crystalloids<sup>2</sup> that contain sodium in the range 130–154 mmol/litre with 5–  
25 10% glucose. **[1.4.7]**

---

<sup>1</sup> At the time of consultation (May 2015), some glucose-free crystalloids did not have a UK marketing authorisation for use in children and young people. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

<sup>2</sup> At the time of consultation (May 2015), some isotonic crystalloids with 5–10% glucose did not have a UK marketing authorisation for use in children and young people. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

- 1 • If there is a risk of water retention associated with non-osmotic antidiuretic  
2 hormone (ADH) secretion, consider restricting fluids to 50–80% of the  
3 routine maintenance needs. **[1.4.9]**

4 **Replacement and redistribution**

- 5 • Use a 0.9% sodium chloride solution for initial fluid replacement and  
6 redistribution. **[1.5.2]**

7 **Managing hyponatraemia that develops during intravenous fluid therapy**

- 8 • If asymptomatic hyponatraemia develops in neonates, children and young  
9 people, review the fluid status and take action as follows:
- 10 – If a child is prescribed a hypotonic fluid, change to an isotonic fluid (for  
11 example, 0.9% sodium chloride).
- 12 – Restrict maintenance IV fluids in children and young people who are  
13 hypervolaemic or at risk of hypervolaemia (for example, if there is a risk  
14 of increased ADH secretion). **[1.7.1]**
- 15 • Be aware that the following symptoms are associated with acute  
16 hyponatraemia during IV fluid therapy:
- 17 – Headache.
- 18 – Nausea and vomiting.
- 19 – Confusion and disorientation.
- 20 – Irritability.
- 21 – Lethargy.
- 22 – Reduced consciousness.
- 23 – Convulsions.
- 24 – Coma.
- 25 – Apnoea. **[1.7.2]**

26  
27

## 1 **1 Recommendations**

2 The following guidance is based on the best available evidence. The [full](#)  
3 [guideline](#) [\[hyperlink to be added for final publication\]](#) gives details of the  
4 methods and the evidence used to develop the guidance.

### 5 ***Terms used in this guideline***

#### 6 **Neonates, children and young people are defined as follows:**

- 7 • neonates: infants aged 28 days and under (born at term)
- 8 • children: 29 days to under 12 years
- 9 • young people: 12 to under 16 years.

10 **Expert:** In this guideline, the term 'expert' refers to a healthcare professional  
11 who has core competencies to diagnose and manage acute illness. These  
12 competencies can be delivered by a variety of models at a local level, such as  
13 a critical care outreach team, a hospital-at-night team or a specialist trainee in  
14 an acute medical or surgical specialty.

### 15 **1.1 Principles and protocols for intravenous fluid therapy**

16 1.1.1 For guidance on the principles and protocols for intravenous (IV)  
17 fluid therapy, see [section 1.1](#) in the NICE guideline on [intravenous](#)  
18 [fluid therapy in adults](#) (recommendations 1.1.1–1.1.3 and 1.1.5–  
19 1.1.8 apply to all ages).

20 1.1.2 Offer IV fluid therapy as part of a protocol (see [Algorithms for IV](#)  
21 [fluid therapy in children and young people in hospital](#)):

- 22 • Assess fluid and electrolyte needs following [Algorithm 1:](#)  
23 [Assessment and monitoring](#).
- 24 • If neonates, children and young people need IV fluids for fluid  
25 resuscitation, follow [Algorithm 2: Fluid resuscitation](#).
- 26 • If neonates, children and young people need IV fluids for routine  
27 maintenance, follow [Algorithm 3: Routine maintenance](#).

- 1           • If neonates, children and young people need IV fluids to address
- 2           existing deficits or excesses, ongoing abnormal losses or
- 3           abnormal fluid distribution, follow [Algorithm 4: Replacement and](#)
- 4           [redistribution](#).
- 5           • If hypernatraemia develops, follow [Algorithm 5: Managing](#)
- 6           [hypernatraemia that develops during IV fluid therapy](#).
- 7           • If hyponatraemia develops, follow [Algorithm 6: Managing](#)
- 8           [hyponatraemia that develops during IV fluid therapy](#).

## 9    **1.2    Assessment and monitoring**

10  1.2.1    Use body weight to calculate IV fluid and electrolyte needs for

11           neonates, children and young people.

12  1.2.2    Consider using body surface area to calculate IV fluid and

13           electrolyte needs if accurate calculation of insensible losses is

14           important (for example, if the weight is above the 91<sup>st</sup> centile, or

15           with acute kidney injury or cancer).

16  1.2.3    In neonates, children and young people who are receiving IV fluids,

17           assess and document the following on the fluid balance and

18           prescription chart:

- 19           • Actual or estimated body weight from the previous day, the
- 20           current day and the difference between the 2, or body surface
- 21           area if used (see recommendation 1.2.2).
- 22           • Fluid input, output and balance over the previous 24 hours.
- 23           • Any special instructions for prescribing, including relevant
- 24           history.
- 25           • An assessment of the fluid status.
- 26           • The results of laboratory and point-of-care assessments,
- 27           including:
  - 28           – full blood count
  - 29           – urea
  - 30           – creatinine

- 1                   – plasma electrolyte concentrations (including chloride, sodium  
2                   and potassium; see recommendation 1.2.4)  
3                   – blood glucose (see recommendation 1.2.5)  
4                   – urinary electrolyte concentrations.
- 5                   • Details of any ongoing losses (see recommendation 1.5.1 and  
6                   the [diagram of ongoing losses](#)).
  - 7                   • Calculations of fluid needs for routine maintenance,  
8                   replacement, redistribution and resuscitation.
  - 9                   • The fluid and electrolyte prescription (in ml per hour), with clear  
10                  signatures, dates and times.
  - 11                  • Fluid limits.
  - 12                  • Types and volumes of fluid input and output (urine, gastric and  
13                  other), recorded hourly and with running totals.
  - 14                  • 12-hourly fluid balance subtotals.
  - 15                  • 24-hourly fluid balance totals.
  - 16                  • 12-hourly reassessments of:
    - 17                  – the fluid prescription
    - 18                  – current hydration status
    - 19                  – whether oral fluids can be started
    - 20                  – potassium requirements
    - 21                  – urine and other outputs.
- 22    1.2.4        Measure plasma electrolyte concentrations using laboratory tests at  
23                   least every 24 hours, and more frequently if there are electrolyte  
24                   disturbances.
- 25    1.2.5        Measure blood glucose at least every 24 hours, and more  
26                   frequently if there is a risk of hypoglycaemia.
- 27    1.2.6        Consider point-of-care testing for measuring plasma electrolyte  
28                   concentrations and blood glucose in time-critical situations when IV  
29                   fluids are needed (for example during emergency situations and in  
30                   A&E, theatre and critical care).

- 1 1.2.7 Diagnose clinical dehydration and hypovolaemic shock using the  
 2 clinical features listed in table 1, but be aware that it can be difficult  
 3 to identify the clinical features in neonates.

4 **Table 1: Clinical features of dehydration and hypovolaemic shock**

No clinically detectable dehydration	Clinical dehydration	Hypovolaemic shock
Alert and responsive	<b>Red flag</b> Altered responsiveness (for example, irritable, lethargic)	Decreased level of consciousness
Appears well	<b>Red flag</b> Appears to be unwell or deteriorating	–
Eyes not sunken	<b>Red flag</b> Sunken eyes	–
Moist mucous membranes (except after a drink)	Dry mucous membranes (except for 'mouth breather')	–
Normal blood pressure	Normal blood pressure	Hypotension (decompensated shock)
Normal breathing pattern	<b>Red flag</b> Tachypnoea	Tachypnoea
Normal capillary refill time	Normal capillary refill time	Prolonged capillary refill time
Normal heart rate	<b>Red flag</b> Tachycardia	Tachycardia
Normal peripheral pulses	Normal peripheral pulses	Weak peripheral pulses
Normal skin turgor	<b>Red flag</b> Reduced skin turgor	–
Normal urine output	Decreased urine output	–
Skin colour unchanged	Skin colour unchanged	Pale or mottled skin
Warm extremities	Warm extremities	Cold extremities

5

6 **Notes:**

- 7 Within the category of 'clinical dehydration' there is a spectrum of severity indicated  
 8 by increasingly numerous and more pronounced clinical features. For hypovolaemic  
 9 shock, one or more of the clinical features listed would be expected to be present.  
 10 Dashes (–) indicate that these features do not specifically indicate hypovolaemic  
 11 shock. This table has been adapted from [section 1.2](#) in the NICE guideline on  
 12 [diarrhoea and vomiting in children](#).

1    **1.3        *Fluid resuscitation***

2    1.3.1        If children and young people need IV fluid resuscitation, use  
3                glucose-free crystalloids<sup>3</sup> that contain sodium in the range 130–  
4                154 mmol/litre, with a bolus of 20 ml/kg over less than 10 minutes.

5    1.3.2        If neonates need IV fluid resuscitation, use glucose-free  
6                crystalloids<sup>3</sup> that contain sodium in the range 130–154 mmol/litre,  
7                with a bolus of 10–20 ml/kg over less than 10 minutes.

8    1.3.3        For neonates, children and young people who have hypovolaemic  
9                shock due to blood loss and need IV fluid resuscitation, use  
10               glucose-free crystalloids<sup>3</sup> that contain sodium in the range 130–  
11               154 mmol/litre, with a bolus of 10 ml/kg over less than 10 minutes.

12   1.3.4        For guidance on using IV fluids for fluid resuscitation in children  
13                and young people with diabetic ketoacidosis, see the NICE  
14                guideline on diabetes in children [\[hyperlink to be added at](#)  
15                [publication\]](#)<sup>4</sup>.

16   1.3.5        Reassess neonates, children and young people after completion of  
17                the IV fluid bolus, and decide whether further fluids are needed.

18   1.3.6        Seek [expert](#) advice if 40–60 ml/kg of IV fluid is needed as part of  
19                the initial fluid resuscitation.

20   **1.4        *Routine maintenance***

21   1.4.1        Calculate routine maintenance IV fluid rates for children and young  
22                people using the Holliday–Segar formula (100 ml/kg/day for the first  
23                10 kg of weight, 50 ml/kg/day for the next 10 kg and 20 ml/kg/day  
24                for any remaining weight).

---

<sup>3</sup> At the time of consultation (May 2015), some glucose free-crystalloids did not have a UK marketing authorisation for use in children and young people. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

<sup>4</sup> NICE is developing guidance on [major trauma](#), which will include the use of IV fluids for fluid resuscitation. Publication is expected in 2016.



- 1 1.4.2 Calculate routine maintenance IV fluid rates for neonates according  
2 to their age, using the following as a guide:
- 3 • From birth to day 1: 50–60 ml/kg/day.
  - 4 • Day 2: 70–80 ml/kg/day.
  - 5 • Day 3: 80–100 ml/kg/day.
  - 6 • Day 4: 100–120 ml/kg/day.
  - 7 • Days 5–28: 120–150 ml/kg/day.
- 8 1.4.3 If children and young people need IV fluids for routine  
9 maintenance, initially use isotonic crystalloids<sup>5</sup> that contain sodium  
10 in the range 130–154 mmol/litre.
- 11 1.4.4 Measure plasma electrolyte concentrations and blood glucose  
12 when starting IV fluids for routine maintenance (except before most  
13 elective surgery), and at least every 24 hours thereafter.
- 14 1.4.5 Be aware that plasma electrolyte concentrations and blood glucose  
15 are not routinely measured before elective surgery unless there is a  
16 need to do so, based on the child's medical condition or the type of  
17 surgery.
- 18 1.4.6 Base any subsequent IV fluid prescriptions on the plasma  
19 electrolyte concentrations and blood glucose measurements.
- 20 1.4.7 If neonates need IV fluids for routine maintenance, initially use  
21 isotonic crystalloids<sup>5</sup> that contain sodium in the range 130–  
22 154 mmol/litre with 5–10% glucose.
- 23 1.4.8 For neonates in critical postnatal adaptation phase (for example,  
24 neonates with respiratory distress syndrome, meconium aspiration,

---

<sup>5</sup> At the time of consultation (May 2015), some isotonic crystalloids with 5–10% glucose did not have a UK marketing authorisation for use in children and young people. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

1 hypoxic ischaemic encephalopathy), give no or minimal sodium  
2 until postnatal diuresis with weight loss occurs.

3 1.4.9 If there is a risk of water retention associated with non-osmotic  
4 antidiuretic hormone (ADH) secretion, consider restricting fluids to  
5 50–80% of the routine maintenance needs.

6 1.4.10 When using body surface area to calculate IV fluid needs for  
7 routine maintenance (see recommendation 1.2.2), estimate  
8 insensible losses within the range 300–400 ml/m<sup>2</sup>/24 hours and  
9 add to urinary output.

## 10 **1.5 Replacement and redistribution**

11 1.5.1 If neonates, children and young people need IV fluids for  
12 replacement or redistribution, adjust the IV prescription (add to  
13 maintenance needs) to account for existing fluid and/or electrolyte  
14 deficits or excesses, ongoing losses (see the [diagram of ongoing](#)  
15 [losses](#)) or abnormal distribution.

16 1.5.2 Use a 0.9% sodium chloride solution for initial fluid replacement  
17 and redistribution.

18 1.5.3 Consider Hartmann's solution for peri-operative redistribution  
19 losses.

20 1.5.4 Use a 0.9% sodium chloride solution containing potassium to  
21 replace ongoing losses (see the [diagram of ongoing losses](#)).

22 1.5.5 Base any subsequent fluid prescriptions on the plasma electrolyte  
23 concentrations and blood glucose measurements.

## 24 **1.6 Managing hypernatraemia that develops during** 25 **intravenous fluid therapy**

26 1.6.1 If hypernatraemia develops in neonates, children and young  
27 people, review the fluid status and take action as follows:

- 1                   • If there is no evidence of dehydration and an isotonic fluid is  
2                   being used, consider changing to a hypotonic fluid (for example,  
3                   0.45% sodium chloride with glucose)<sup>6</sup>.
- 4                   • If dehydration is diagnosed, calculate the water deficit and  
5                   replace it over 48 hours, initially with 0.9% sodium chloride.
- 6                   • If the fluid status is uncertain, measure urine sodium and  
7                   osmolality.
- 8                   • If hypernatraemia worsens or is unchanged after replacing the  
9                   deficit, review the fluid type and consider changing to a  
10                  hypotonic solution (for example, 0.45% sodium chloride with  
11                  glucose).

12   1.6.2        When correcting hypernatraemia, ensure that the rate of fall of  
13                  plasma sodium does not exceed 12 mmol/litre in a 24 hour period.

14   1.6.3        Measure plasma electrolyte concentrations every 4–6 hours for the  
15                  first 24 hours, and after this base the frequency of further plasma  
16                  electrolyte measurements on the treatment response.

## 17   **1.7        *Managing hyponatraemia that develops during*** 18                  ***intravenous fluid therapy***

19   1.7.1        If asymptomatic hyponatraemia develops in neonates, children and  
20                  young people, review the fluid status and take action as follows:

- 21                  • If a child is prescribed a hypotonic fluid, change to an isotonic  
22                  fluid (for example, 0.9% sodium chloride).
- 23                  • Restrict maintenance IV fluids in children and young people who  
24                  are hypervolaemic or at risk of hypervolaemia (for example, if  
25                  there is a risk of increased ADH secretion).

---

<sup>6</sup> At the time of consultation (May 2015), some hypotonic solutions did not have a UK marketing authorisation for use in children and young people. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

1 1.7.2 Be aware that the following symptoms are associated with acute  
2 hyponatraemia during IV fluid therapy:

- 3 • Headache.
- 4 • Nausea and vomiting.
- 5 • Confusion and disorientation.
- 6 • Irritability.
- 7 • Lethargy.
- 8 • Reduced consciousness.
- 9 • Convulsions.
- 10 • Coma.
- 11 • Apnoea.

12 1.7.3 If acute symptomatic hyponatraemia develops in neonates, children  
13 and young people, review the fluid status, seek immediate [expert](#)  
14 advice and take action as follows:

- 15 • Consider a bolus of 2 ml/kg (maximum 100 ml) of 2.7% saline  
16 over 10–15 minutes.
- 17 • Consider a further bolus of 2 ml/kg (maximum 100 ml) of 2.7%  
18 saline over the next 10–15 minutes if symptoms are still present  
19 after the initial bolus.
- 20 • If symptoms are still present after the second bolus, check the  
21 plasma sodium level and consider a third bolus of 2 ml/kg  
22 (maximum 100 ml) of 2.7% saline over 10–15 minutes.
- 23 • Measure the plasma sodium concentration at least hourly.
- 24 • As symptoms resolve, decrease the frequency of plasma sodium  
25 measurements based on the response to treatment.

26 1.7.4 Do not manage acute hyponatraemia encephalopathy using fluid  
27 restriction alone.


28 1.7.5 After hyponatraemia symptoms have resolved, ensure that the rate  
29 of increase of plasma sodium does not exceed 12 mmol/litre in a  
30 24-hour period.


1    **1.8**        ***Training and education***

2    1.8.1        For guidance on training and education for healthcare professionals  
3                involved in prescribing and delivering IV fluid therapy, see [section](#)  
4                [1.6](#) in the NICE guideline on [intravenous fluid therapy in adults](#).


Algorithms for IV fluid therapy in children and young people in hospital

**Algorithm 1: Assessment and monitoring**





**Algorithm 3: Routine Maintenance**





**Algorithm 4: Replacement and Redistribution**

Adjust the IV fluid prescription to account for existing fluid and/or electrolyte deficits or excesses, ongoing losses or abnormal distribution

Perioperative redistribution losses?

No

Yes

Use 0.9% sodium chloride as the initial fluid

Consider Hartmann's solution

Need to replace ongoing losses?

No


Yes

Use 0.9% sodium chloride containing potassium to replace ongoing losses

Base subsequent fluid composition on plasma electrolyte concentrations and blood glucose measurements

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12

**Algorithm 5: Managing hypernatraemia that develops during IV fluid therapy**




1

**Algorithm 6: Managing hyponatraemia that develops during IV fluid therapy**


Be aware that the following symptoms are associated with acute hyponatraemia:

- Headache
- Nausea and vomiting
- Confusion and disorientation
- Irritability
- Lethargy
- Reduced consciousness
- Convulsions
- Coma
- Apnoea



1 **Diagram of ongoing losses**

Download the PDF [here](#). [hyperlink to be added for final publication]



2

3 Source: Copyright – National Clinical Guideline Centre

4

1

## 2       **2       Research recommendations**

3       The Guideline Development Group has made the following recommendations  
4       for research, based on its review of evidence, to improve NICE guidance and  
5       patient care in the future. The Guideline Development Group's full set of  
6       research recommendations is detailed in the [full guideline](#). [hyperlink to be  
7       added for final publication]

### 8       **2.1       Complications of IV fluid therapy**

9       What is the incidence of complications during, and as a consequence of, IV  
10      fluid therapy in children and young people?

#### 11      **Why this is important**

12      Every day, children and young people are prescribed IV fluid therapy for a  
13      variety of reasons. However, there is little evidence on IV fluids in children and  
14      young people, and the limited evidence available is of very poor quality.

15      Complications of IV fluid therapy can lead to mortality and significant morbidity  
16      for the patient. This, in turn, represents a cost burden for the NHS in terms of  
17      critical care admissions, prolonged inpatient stays or the potential need for  
18      long-term follow-up and care by medical and allied healthcare professionals.

### 19      **2.2       Glucose concentration**

20      What is the most appropriate glucose concentration in IV fluids for children  
21      and young people of different ages?

#### 22      **Why this is important**

23      In recent years, the use of glucose-containing hypotonic IV fluids in children  
24      and young people has been questioned, because of the risk of  
25      hyponatraemia. Many children and young people are now prescribed non-  
26      glucose-containing isotonic IV fluids for maintenance. However, there are  
27      several groups of children and young people, in particular, neonates and  
28      some children in the peri-operative period (for example, those who underwent  
29      prolonged fasting preoperatively, and those who had central blocks during

1 anaesthesia), who may benefit from glucose-containing IV solutions to prevent  
2 hypoglycaemia. A blanket prescription of 5 or 10% glucose solution for all may  
3 result in hyperglycaemia in some children and young people. However, the  
4 use of IV fluids containing lower concentrations of glucose may be sufficient to  
5 prevent hypoglycaemia and also avoid unnecessary hyperglycaemia. This  
6 may have a clinical application across all age groups, including neonates.

### 7 **2.3      *Fluid balance charts***

8 For children and young people receiving IV fluids, does the use of a  
9 standardised national fluid balance chart reduce the rate of complications  
10 arising as a result of prescription and/or administration errors?

#### 11 **Why this is important**

12 The National Confidential Enquiry into Perioperative Deaths reports in 1999  
13 and 2009 identified problems in fluid management in patients in the UK. A lack  
14 of consistency in prescribing and recording IV fluids may contribute to this. A  
15 lack of familiarity of 'mobile' medical and nursing staff with fluid balance charts  
16 in different hospital settings may further increase the likelihood of prescription  
17 and administration errors.

18 A prospective cohort of children and young people receiving IV fluids,  
19 prescribed and documented on a standardised national fluid balance chart, or  
20 a case–control study comparing the use of a standardised national fluid  
21 balance chart with non-standard 'local' fluid balance charts is needed to  
22 assess the clinical and cost effectiveness of using a standardised national  
23 fluid balance chart. Outcomes should include complications of IV fluid therapy  
24 (hypovolaemia, hypervolaemia, electrolyte abnormalities, neurological  
25 complications and hypoglycaemia) and incidence of prescription errors. If  
26 using a standardised national fluid balance chart resulted in better fluid  
27 prescription and clinical outcomes in children and young people, this would  
28 have significant cost implications for the NHS.

### 29 **2.4      *Training and education of healthcare professionals***

30 Does ensuring that all hospital healthcare professionals involved in  
31 prescribing and delivering IV fluids for children and young people are

1 appropriately trained in the principles of fluid prescribing and IV fluid therapy-  
2 related complications lead to a reduction in IV fluid-related complications and  
3 associated healthcare costs?

#### 4 **Why this is important**

5 Assessing patients' IV fluid needs, as well as prescribing and delivering IV  
6 fluids, are essential daily tasks on most paediatric wards. These are complex  
7 responsibilities that entail careful clinical and assessment, good  
8 understanding of the physiology of fluid homeostasis both in health and  
9 disease, and appropriate supervision and training. There is currently no  
10 standard training provided for healthcare professionals working in the UK. Any  
11 teaching at both undergraduate and postgraduate level is currently delivered  
12 *ad hoc*, and in many cases may be limited. If fluid management in hospitalised  
13 children and young people is to improve, standardised training is likely to be  
14 needed. Any educational interventions made would need to be evaluated to  
15 assess whether practice had subsequently improved.

### 16 **3 Other information**

#### 17 **3.1 Scope and how this guideline was developed**

18 NICE guidelines are developed in accordance with a [scope](#) that defines what  
19 the guideline will and will not cover.

#### **How this guideline was developed**

NICE commissioned the National Clinical Guideline Centre to develop this guideline. The Centre established a Guideline Development Group (see section 4), which reviewed the evidence and developed the recommendations.

The methods and processes for developing NICE clinical guidelines are described on the [NICE website](#).

## 1 **3.2 Related NICE guidance**

2 Details are correct at the time of consultation on the guideline (May 2015).

3 Further information is available on [the NICE website](#).

### 4 **Published**

#### 5 **General**

- 6 • [Medicines adherence](#) (2009) NICE guideline CG76

#### 7 **Condition-specific**

- 8 • [Intravenous fluid therapy in adults in hospital](#) (2013) NICE guideline CG174
- 9 • [Acute kidney injury](#) (2013) NICE guideline CG169
- 10 • [Feverish illness in children](#) (2013) NICE guideline CG160
- 11 • [Neutropenic sepsis](#) (2012) NICE guideline CG151
- 12 • [Sedation in children and young people](#) (2010) NICE guideline CG112
- 13 • [Bacterial meningitis and meningococcal septicaemia](#) (2010) NICE guideline
- 14 CG102
- 15 • [Diarrhoea and vomiting in children](#) (2009) NICE guideline CG84
- 16 • [Urinary tract infection in children](#) (2007) NICE guideline CG54
- 17 • [Pre-hospital initiation of fluid replacement therapy in trauma](#) (2004) NICE
- 18 technical appraisal guidance TA74

### 19 **Under development**

20 NICE is [developing](#) the following guidance:

- 21 • [Medicines optimisation](#). NICE guideline. Publication expected March 2015.
- 22 • [Bronchiolitis in children](#). NICE guideline. Publication expected May 2015.
- 23 • [Diabetes in children and young people](#). NICE guideline. Publication
- 24 expected August 2015.
- 25 • [Transfusion](#). NICE guideline. Publication expected October 2015.
- 26 • [Neonatal jaundice](#). NICE guideline. Publication expected November 2015.
- 27 • [Major trauma](#). NICE guideline. Publication expected February 2016.

28



1 **4 The Guideline Development Group, National**  
2 **Collaborating Centre and NICE project team,**  
3 **and declarations of interests**

4 **4.1 Guideline Development Group (GDG)**

5 **Peter Crean (Chair)**

6 Consultant Paediatric Anaesthetist, Royal Belfast Hospital for Sick Children

7 **Jan Dudley**

8 Consultant Paediatric Nephrologist, Bristol Royal Hospital for Children

9 **Deborah Evans**

10 Paediatric Nurse Practitioner, Children's Hospital for Wales, Cardiff

11 **Andrew Fitzsimons**

12 Consultant in Paediatric Emergency, Royal Belfast Hospital for Sick Children

13 **Chris Gildersleve**

14 Consultant Paediatric Anaesthetist, Children's Hospital for Wales, Cardiff

15 **Lyda Jadresic**

16 Consultant General Paediatrician with a special interest in paediatric  
17 nephrology, Gloucestershire Royal Hospital

18 **Ann Kelly**

19 Advanced Paediatric Nurse Practitioner, EMBRACE, Yorkshire and Humber  
20 Infant and Children's Transport Service, Barnsley

21 **Jayne Kranat**

22 Patient and Carer Member

23 **Clodagh Loughery (co-opted member)**

24 Consultant Clinical Pathologist

25 **Aung Soe**

26 Consultant Neonatologist, Medway Maritime Hospital

1 **Stephanie Warne**

2 Locum Consultant in Paediatric Surgery and Urology, Oxford Children's  
3 Hospital

4 **Andrew Wignell**

5 Specialist Clinical Pharmacist, Nottingham University Hospital

6 **Peter Wilson**

7 Paediatric Intensive Care Consultant and Clinical Director, Southampton  
8 Children's Hospital

9 **4.2 National Clinical Guideline Centre**

10 **Joanna Ashe**

11 Senior Information Scientist

12 **Katie Broomfield**

13 Document Editor/Process Assistant

14 **Dalia Dawoud (from August 2014)**

15 Health Economist

16 **Elisabetta Fenu**

17 Health Economic Lead

18 **Edward Griffin (until August 2014)**

19 Health Economist

20 **Jennifer Hill (until April 2014)**

21 Operations Director

22 **Katie Jones**

23 Senior Project Manager

24 **Julie Neilson**

25 Senior Research Fellow

26 **Frank O'Neill**

27 Senior Research Fellow

1 **Gill Ritchie (from April 2014)**

2 Associate Director

3 **Cheentan Singh**

4 Consultant Paediatrician

5 **4.3 NICE project team**

6 **Sharon Summers-Ma**

7 Guideline Lead

8 **Mark Baker**

9 Clinical Adviser

10 **Caroline Keir**

11 Guideline Commissioning Manager (from December 2014)

12 **Katie Perryman-Ford**

13 Guideline Commissioning Manager (until November 2014)

14 **Jennifer Wells**

15 Guideline Coordinator

16 **Steven Barnes**

17 Technical Lead

18 **Paul Crosland**

19 Health Economist

20 **Sarah Palombella**

21 Editor

22 **4.4 Declarations of interests**

23 The following members of the Guideline Development Group made  
24 declarations of interests. All other members of the Group stated that they had  
25 no interests to declare.

DRAFT FOR CONSULTATION

<b>Member</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Peter Crean	Invited to write 2 journal articles on fluid and electrolyte balance in children. One of these is for Anaesthesia and Intensive Care Medicine and the other is for Paediatrics and Child Health. No honorarium received.	Personal non-pecuniary interest	Declare and participate
	Invited to give a talk on IV fluids on 'When things go wrong' at the annual conference of the European Society of Paediatric Anaesthesiology in Prague on 18/9/2014. Travel expenses and hotel accommodation provided as part of the package for all speakers at the conference. No honorarium received.	Personal non-pecuniary interest	Declare and participate
Chris Gildersleve	Received accommodation and travel expenses as an invited speaker at the 2014 APA Annual Scientific Meeting 15-16 May 2014	Personal non-pecuniary interest	Declare and participate
	Invited to speak on IV fluids in children at the Current Concepts meeting at the RCoA, London on 21/11/2014. No honorarium received; travel and accommodation expenses covered.	Personal non-pecuniary interest	Declare and participate
	Invited to speak on IV fluids in children at the Paediatric CPD study day at the RCoA, London on 4/3/2015. No honorarium received; though travel and accommodation expenses covered.	Personal non-pecuniary interest	Declare and participate

1